Results 61 to 70 of about 4,618 (150)
Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations [PDF]
, 2017 肺癌是世界上死亡率和发病率增长最快，对人类健康和生命威胁最大的恶性肿瘤。非小细胞肺癌（NSCLC）含有多种细胞类型，占据新发肺癌患者的85%。吸烟仍是主要危险因素，不断恶化的大气污染也渐渐在肺癌成因中占据一席之地。目前，肺癌的治疗方法是以外科手术为中心，多种治疗方式如放化疗配合的综合治疗。由于大多数非小细胞肺癌患者就诊时便已处于晚期，能手术的患者只占一小部分。目前临床常用的化疗药物副作用较大，收益相对有限。近年来，得益于癌驱动基因的发现与研究，靶向治疗成为了中晚期非小细胞肺癌新的临床治疗方法 ...
马逸涵
core
Analysis of Differentially Expressed Proteins in Self-Paired Sera of Advanced Non-small Cell Lung Cancer Patients Responsive to Gefin [PDF]
, 2009 Background and objective All the advanced NSCLC patients that received EGFR-TKI therapy will eventually relapse after a period of efficacy. The aim of this study is to investigate the serum biomarkers as potential predictive factors for the efficacy of ...
Ailin GUO +10 more
core
Zhongguo shiyan zhenduanxue, 2012 本研究探讨增殖细胞核抗原（Proliferating Cell Nuclear Antigen,PCNA）与Mina53在非小细胞肺癌中的表达极其与放疗患者疗效的相关性,从而为早期预测非小细胞肺癌放疗敏感性提供依据,现报道如下。1资料与方法1 ...
赵光日
doaj
The Analysis of Erlotinib on Brain Metastases in Patients with Non-small-cell Lung Cancer [PDF]
, 2009 Background and objective Brain metastases are common in non-small-cell lung cancer (NSCLC) and the prognosis is poor. Erlotinib is a specific inhibitor of the epidermal growth factor receptor-associated tyrosine kinase (EGFRTKI), which has been gradually
Baohui HAN, Hao BAI
core
Zhongguo shiyan zhenduanxue, 2012 非小细胞肺癌（non-small cell lung cancer,NSCLC）约占肺癌总数的75%-80%[1],随着社会工业化的不断发展和人口的老龄化,不同年龄段肺癌从发病因素和临床诊断各方面呈现出新的特点。本文收集了自2005年至2011年我院胸外科收治的1500例非小细胞肺癌患者的临床资料 ...
焦宏博, 李长锋, 李丹丹, 辛华
doaj
The Expressions of IL-7 and IL-7R and the Relationship between them with Lymph Node Metastasis and Prognosis in Non-small Cell Lung Cancer [PDF]
, 2010 Background and objective It has been proven that lymph node metastasis was closely related to prognosis of lung cancer. Interleukin-7 (IL-7) and interleukin-7 receptor (IL-7R) could promote lymph node metastasis through vascular endothelial growth factor-
Jian MING +4 more
core
Zhongguo shiyan zhenduanxue, 2019 肺癌(lung cancer,LC)作为全球最常见的恶性肿瘤[1],病理分型包括小细胞肺癌(small cell lung cancer,SCLC)和非小细胞肺癌(non-small cell lung cancer,NSCLC)[2],非小细胞肺癌约占所有肺癌80%[3,4]。研究表明,吸烟、喝酒、遗传因素及环境污染等均是诱发NSCLC的重要因素[3,5]。通常,手术、生物疗法或放/化疗是治疗NSCLC的主要方法[6]。然而 ...
冯为
doaj
Zhongshan Daxue xuebao. Yixue kexue ban, 2020 【目的】探究miR-204-3p 靶向EphB2 基因对非小细胞肺癌增殖、凋亡、侵袭的调控机制。【方法】培养将非小细胞肺癌A549 细胞系分为 5 组 NC mimic 组（miR-204-3p 过表达阴性对照组）、miR-204-3p mimic 组（miR-204-3p 过表达组）、oe-NC 组（EphB2 过表达阴性对照组）、oe-EphB2 组（EphB2 过表达组）、miR-204-3p mimic+oe-EphB2 组（miR-204-3p 与EphB2 均过表达组）。MTT、流式细胞术 ...
谢传华 +7 more
doaj
Analysis of Differential Gel Electrophoresis of Paclitaxol Resistant and Sensitive Lung Adenocarcinoma Cells' Secretome [PDF]
, 2009 Background and objective Paclitaxol (PTX) resistance is one of main factors which affect the outcome of chemotherapy of lung adenocarcinoma. The aim of this study is to compare the secreted protein expression profiles between Paclitaxol (PTX) resistant ...
Huifang SHA +5 more
core
Zhongguo shiyan zhenduanxue, 2011 目的探讨非小细胞肺癌（NSCLC）组织中趋化因子受体（CXCR4）的表达与肺癌生物学行为以及血管形成之间的关系,着重分析CXCR4的表达以及新生血管形成在肺癌侵袭、转移及预后中的生物学意义。方法应用免疫组织化学方法 （SP法）检测62例非小细胞肺癌组织、12例癌旁正常组织中CXCR4的表达及微血管密度（MVD）的值,并分析CXCR4的表达及MVD与组织类型、肿瘤大小、TNM分期、分化程度、淋巴结转移的相关性。结果 CXCR4在肺癌组织中的阳性表达率为58.1%,在正常组织中的阳性表达率为16.7 ...
席妍, 王彦荣, 宋阳
doaj